ImmuPharma (LON:IMM) Stock Price Up 25.3% - Should You Buy?

Key Points

• ImmuPharma plc's stock price surged by 25.3% on Tuesday, climbing to GBX 10.10 ($0.14) after closing at GBX 8.06 ($0.11).
• Approximately 37.5 million shares were traded, marking a 400% increase in volume compared to the average daily trading.
• The company reported a negative return on equity of 131.41% and is expected to post earnings per share of -£339 for the current fiscal year.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) were up 25.3% on Tuesday . The company traded as high as GBX 10.50 ($0.14) and last traded at GBX 10.10 ($0.14). Approximately 37,546,863 shares were traded during mid-day trading, an increase of 400% from the average daily volume of 7,505,706 shares. The stock had previously closed at GBX 8.06 ($0.11).

ImmuPharma Stock Performance

The stock has a fifty day simple moving average of GBX 2.38 and a two-hundred day simple moving average of GBX 2.70. The stock has a market cap of £50.47 million, a price-to-earnings ratio of -1,134.83 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Equities analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.